More About Vijay
Vijay Pande, PhD, is a General Partner and has been at Andreessen Horowitz since 2014. He founded and leads a16z Bio + Health, which invests in life sciences and healthcare through four dedicated funds with more than $3 billion under management. Vijay leads the firm’s investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances that take bio beyond healthcare. He is also an Adjunct Professor of Structural Biology at Stanford University. He currently sits on the boards of Alpine Bio, Apeel Sciences, BioAge, Devoted Health, Freenome, Function Health, Genesis Therapeutics, Inceptive Therapeutics, insitro, Nautilus Biotechnology, Omada Health, Q.bio, and Scribe Therapeutics.
Prior to joining Andreessen Horowitz, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, where he led a team of researchers pioneering computational methods and their application to medicine and biology (resulting in over 300 publications and six patents). Vijay was also concurrently the director of the Biophysics program at Stanford, where he led a team of more than 50 faculty members and propelled the program to the top in the country. Vijay also co-founded Globavir Biosciences, and founded the Folding@Home Distributed Computing Project.
Vijay holds a BA in Physics from Princeton University and a PhD in Physics from MIT. He has been awarded the DeLano Prize in Computation, a Guinness World Record for Folding@Home, the American Chemical Society Thomas Kuhn Paradigm Shift Award, and was selected for MIT TR10. In his teens, Vijay was the first employee at video game startup Naughty Dog, maker of Crash Bandicoot and The Last of Us.
Latest Content
-
What if we stopped trying to cure disease and started preventing it instead? In this episode, Dr. Eric Topol joins general partner Vijay Pande, PhD, to unpack the future of aging, prevention, and precision health—as explored in Eric's new book, Super Agers: An Evidence-Based Approach to Longevity.
-
Join a16z general partners Marc Andreessen, Julie Yoo, and Vijay Pande for an incisive exploration of what's driving—and stalling—transformation in healthcare. With the industry now consuming nearly 20% of U.S. GDP yet d...
-
Healthcare is a $4 trillion industry, making up nearly a fifth of the U.S. economy—but despite having some of the best doctors and advanced technology, the system often delivers poor outcomes at skyrocketing costs. Why i...
-
Today, we’re proud to announce we’ve led the Series A for Slingshot, the world’s first foundation model for psychology. This brings the total capital raised for the company to $40 million.
-
What if the biggest challenge of our time isn’t living longer, but living better?
-
Vijay Pande, general partner, and Daisy Wolf, investing partner, join host Steph Smith on this crossover episode of the a16z podcast.
-
Vijay Pande, PhD, founding partner of a16z Bio + Health, joins Derrick Harris, host of the AI + a16z podcast.
-
Casey Means, MD, a Stanford-trained physician, cofounder of Levels, and author of the new book Good Energy, joins Vijay Pande, PhD, founding partner of a16z Bio + Health.
-
Half of prescribed medications are never taken, and 88% of Americans are metabolically unhealthy. Despite spending 20% of our GDP on healthcare—twice that of any other developed nation—our outcomes still lag behind. In t...
-
Bowen Liu, PhD, investing partner, and Surya Ganguli, PhD, venture partner, join Vijay Pande, PhD, general partner of a16z Bio + Health.
-
Vijay Pande walks us through two decades of applying software engineering and AI to biotech and health care — from Folding@Home through AlphaFold and more.
-
In this episode, a follow-up to our episode Grand Challenges in Healthcare AI, Julie Yoo and Vijay Pande, a16z general partners, answer audience questions about AI applications in healthcare.
-
Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.
-
Recently, we invested in Function Health, a company that embodies the vision and excitement we had when writing those theses. The one piece we underestimated is the current state of latent demand among consumers for a new approach to healthcare and longevity.
-
The most impactful way to fix healthcare is through improving the consumer experience, which has been largely ignored to date. In today’s modern world where you can order groceries, buy flight tickets, and wire money from your phone, taking care of yourself and navigating the healthcare system remains impossibly hard.
-
In this episode, originally recorded for the a16z Podcast, host Steph Smith interviews Pushmeet Kohli, DeepMind's VP of Research focused on AI for science. They are joined by a16z Bio + Health founding partner Vijay Pand...
-
As Ozempic, Wegovy, Mounjaro, and Zepbound capture the healthcare spotlight, we’ve developed a series of episodes that go beyond the headlines and take you into conversations with the specialists. Our first guest is Carolyn Jasik, MD, Chief Medical Officer at Omada Health.
-
Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health. Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab.
-
In recent years, the AI landscape has seen huge advancements, from the release of Dall-E 2 in April 2022 to the emergence of AI music and video models in early 2024. While creative tools often steal the spotlight, AlphaF...
-
Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.
-
Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.
-
Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.
-
Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.
-
Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.
-
Scribe Therapeutics cofounder and CEO Ben Oakes joins a16z Bio + Health founding general partner Vijay Pande.
-
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.
-
We’re excited to share Raising Health’s first episode here where Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding general partner of Bio + Health.
-
We have long believed that AI will fundamentally reshape biotech and healthcare, positioning us at the brink of an AI-driven Industrial Revolution. But when will we see this payoff? Put more boldly, when will the majority of new drugs be designed with AI?
-
Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit. Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences.
-
Nature’s blueprint – DNA – is an incredibly efficient machine. You cannot see it with the naked eye, yet it can last for hundreds, maybe even millions of years. Plus, the storage capacity of a single gram of DNA is over 200 million gigabytes! As the cost of DNA sequencing (reading) and synthesis (writing) comes down, scientists are looking to our very own biology for applications reaching as far as data storage. Learn more about this fascinating world with a16z General Partner Vijay Pande, as he says, this next wave of biological computing will “be the mother of many new exponentials to come.”
-
Bio Eats World is now Raising Health! On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.
-
100% of stock trades used to be made by humans. Today, 80% are made by computer algorithms. AI is about to bring a similar revolution to healthcare. Over the next few decades, at least half of the $4.3 trillion dollar American healthcare industry will be AI-driven.
-
Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health. In this episode, Pranav and Vijay discuss a future with generalist medical AI. This is the idea of a medical AI that isn’t narrowly tailored to one specific task.
-
Our view is that 1) the latest advancements in AI offer a massive enablement opportunity to support our clinicians and 2) this can’t happen without the help of forward-thinking policymakers laying the infrastructure for AI-enabled care.
-
Miriam Vogel, President and CEO of EqualAI, cohost of the podcast In AI we Trust, and Chair to the recently launched National AI Advisory Committee, joins Vijay Pande of Bio + Health.
-
AI trailblazer Suchi Saria, PhD, in conversation with Vijay Pande, sheds light on the winding path that led her to launch Bayesian Health, a bold effort to infuse intelligence into clinical workflows.
-
Fei-Fei Li, PhD, Professor in the Computer Science Department at Stanford University, and Co-Director of Stanford’s Human-Centered AI Institute, joins Bio + Health founding partner Vijay Pande. In this candid conversation, Li unfolds her transformation from a young immigrant to an influential figure in AI. The conversation explores the birth of ImageNet, a pivotal step that bridged the gap between visual intelligence and accessible AI technology. They delve into the notion of a 'Dignity Economy,' hinting at a future where technology serves to elevate human experience rather than undermine it. Li also touches on the delicate balance between relentless innovation and life's humble pursuits. This episode peels back the layers on the human side of AI, offering a rare glimpse into the personal and professional realms of a pioneer shaping the AI landscape.
-
In this candid conversation, Li unfolds her transformation from a young immigrant to an influential figure in AI. The conversation explores the birth of ImageNet, a pivotal step that bridged the gap between visual intelligence and accessible AI technology.
-
Together, they talk about how Evan’s work in the lab (ironically, Vijay's lab at Stanford!) translated to the creation of Genesis, which is tackling the problem of drug discovery through AI. They also discuss how the Genesis team is building specifically to carry on work at the intersection of ML, biotech, and chemistry.
-
Olga Troyanskaya, PhD, a professor in the department of computer science at Princeton and Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology, joins Vijay Pande, founding partner of a16z Bio + Health.
-
With the rapid pace of innovation in AI and other enabling technologies, it is crucial that we have leaders on our team with deep knowledge of how these tools can be applied to drive meaningful change. That is why we are thrilled to welcome Dr. Surya Ganguli as our newest Venture Partner.
-
Surya Ganguli, PhD, an associate professor at Stanford University and a neural dynamics researcher, joins Vijay Pande of Bio + Health.
-
Today’s episode continues our coverage from a16z’s recent AI Revolution event. You’ll hear a16z Bio & Health GP Vijay Pande speak with Daphne Koller about the fascinating convergence of machine learning and genomics – two industries that have benefitted decades of investment and progress – which are now colliding head on.
-
This episode is live from our recent AI Revolutionaries (AIR) conference. In this episode, Daphne Koller, PhD, founder and CEO at insitro and AI expert, chats with Vijay Pande of Bio + Health.
-
Aviv Regev, PhD, the Head and Executive VP of Genentech Research and Early Development, and founding co-chair of the Human Cell Atlas, joins Vijay Pande on Bio Eats World.
-
Daphne Koller, founder and CEO of insitro, discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultural divide between building with atoms and building with bits.
-
Andrew has thought deeply about the implications of integrating AI into many areas of our lives, going so far as to put out a public social media call for people who believe AI is dangerous to speak with him. He and Vijay discussed this, as well as how AI could become foundational to many industries—and what needs to happen to make that future a reality.
-
Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.
-
Together, Lloyd and Vijay chatted about how AI could change the practice of medicine, and what the implications are for medical students now and in the future. join Lloyd and Vijay as they discuss AI and medical education—from how students learn to how doctors become licensed.
-
Isaac (Zak) Kohane, MD, PhD, the Chair of the Department of Biomedical Informatics at Harvard Medical School, joins Vijay Pande, founding partner of a16z Bio + Health.
-
We believe that any new technology has to be 10 times better to successfully displace the last one – marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.
-
Jeffrey Kaditz, repeat founder and current founder, CEO, and CTO of Q Bio, joins Vijay Pande, founding partner of a16z Bio + Health.
-
The world is amidst an AI-driven industrial revolution. Whether we let it improve the health of Americans is up to how we regulate it. There is no sector where AI can drive more immediate, life-saving impact than in biotechnology and healthcare.
Select Investments
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments. A list of investments made by funds managed by a16z is available here: https://a16z.com/investment-list/.
